6 results
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
score that received at least one dose of study drug and had at least one post-baseline HAMD-17 assessment), and baseline demographics were balanced
424B4
NMRA
Neumora Therapeutics Inc.
18 Sep 23
Prospectus supplement with pricing info
4:12pm
at least one dose of study drug and had at least one post-baseline HAMD-17 assessment), and baseline demographics were balanced between the navacaprant
S-1/A
NMRA
Neumora Therapeutics Inc.
11 Sep 23
IPO registration (amended)
6:07am
of study drug and had at least one post-baseline HAMD-17 assessment), and baseline demographics were balanced between the navacaprant and placebo arms
S-1
NMRA
Neumora Therapeutics Inc.
25 Aug 23
IPO registration
5:03pm
assessment), and baseline demographics were balanced between the navacaprant and placebo arms.
The original trial design, when initiated by BlackThorn
DRS/A
NMRA
Neumora Therapeutics Inc.
9 Aug 23
Draft registration statement (amended)
12:00am
-17 assessment), and baseline demographics were balanced between the navacaprant and placebo arms.
The original trial design, when initiated
DRS/A
qp1v0
30 Jun 23
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next